The FDA approved once-weekly semaglutide for the treatment of obesity among adolescents aged 12 to 17 years with an initial BMI in the 95th percentile for age and sex, according to a press release.
The FDA’s new indication for semaglutide (Wegovy, Novo Nordisk) comes a little more than 6 months after the medication was initially approved in June for chronic weight management in adults with obesity or with overweight plus one weight-related condition. As Healio previously reported, semaglutide was the first drug to be approved for chronic weight management for adults with obesity since